278 related articles for article (PubMed ID: 28471100)
1. Treatment of Bilateral Retinal Angiomatous Proliferation with Anti-vascular Endothelial Growth Factor: 12-Month Outcome.
Kim JM; Kim JH; Chang YS; Kim JW; Kim CG; Lee DW
Korean J Ophthalmol; 2017 Jun; 31(3):240-248. PubMed ID: 28471100
[TBL] [Abstract][Full Text] [Related]
2. Vascularized retinal pigment epithelial detachment in age-related macular degeneration: treatment and RPE tear incidence.
Introini U; Torres Gimeno A; Scotti F; Setaccioli M; Giatsidis S; Bandello F
Graefes Arch Clin Exp Ophthalmol; 2012 Sep; 250(9):1283-92. PubMed ID: 22350060
[TBL] [Abstract][Full Text] [Related]
3. FACTORS INFLUENCING VISUAL ACUITY IN PATIENTS RECEIVING ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR FOR MYOPIC CHOROIDAL NEOVASCULARIZATION.
Iacono P; Battaglia Parodi M; Selvi F; Parravano MC; Chiaravalloti A; Varano M; Bandello F
Retina; 2017 Oct; 37(10):1931-1941. PubMed ID: 28033235
[TBL] [Abstract][Full Text] [Related]
4. Response of vascular pigment epithelium detachment due to age-related macular degeneration to monthly treatment with ranibizumab: the prospective, multicentre RECOVER study.
Clemens CR; Wolf A; Alten F; Milojcic C; Heiduschka P; Eter N
Acta Ophthalmol; 2017 Nov; 95(7):683-689. PubMed ID: 28084038
[TBL] [Abstract][Full Text] [Related]
5. Treatment of choroidal neovascularization using intravitreal bevacizumab.
Pedersen R; Soliman W; Lund-Andersen H; Larsen M
Acta Ophthalmol Scand; 2007 Aug; 85(5):526-33. PubMed ID: 17511757
[TBL] [Abstract][Full Text] [Related]
6. Short-term efficacy of intravitreal Aflibercept injections for retinal angiomatous proliferation.
Chou HD; Wu WC; Wang NK; Chuang LH; Chen KJ; Lai CC
BMC Ophthalmol; 2017 Jun; 17(1):104. PubMed ID: 28655307
[TBL] [Abstract][Full Text] [Related]
7. Intravitreal bevacizumab in vascular pigment epithelium detachment as a result of subfoveal occult choroidal neovascularization in age-related macular degeneration.
Ach T; Hoeh AE; Ruppenstein M; Kretz FT; Dithmar S
Retina; 2010 Oct; 30(9):1420-5. PubMed ID: 20543764
[TBL] [Abstract][Full Text] [Related]
8. Clinical Outcomes of Eyes with Submacular Hemorrhage Secondary to Age-related Macular Degeneration Treated with Anti-vascular Endothelial Growth Factor.
Kim KH; Kim JH; Chang YS; Lee TG; Kim JW; Lew YJ
Korean J Ophthalmol; 2015 Oct; 29(5):315-24. PubMed ID: 26457037
[TBL] [Abstract][Full Text] [Related]
9. Anatomical and visual outcomes of ranibizumab injections in retinal pigment epithelium tears.
Erol MK; Ozdemir O; Coban DT; Ceran BB; Sari ES
Arq Bras Oftalmol; 2015; 78(3):168-72. PubMed ID: 26222106
[TBL] [Abstract][Full Text] [Related]
10. [Retinal angiomatous proliferation with associated pigment epithelium detachment: anti-VEGF therapy].
Lommatzsch A; Heimes B; Gutfleisch M; Spital G; Dietzel M; Pauleikhoff D
Ophthalmologe; 2011 Mar; 108(3):244-51. PubMed ID: 20571805
[TBL] [Abstract][Full Text] [Related]
11. Long-term visual outcome and prognostic factors of Intravitreal anti-vascular endothelial growth factor treatment for retinal angiomatous proliferation.
Cho HJ; Lee TG; Han SY; Kim HS; Kim JH; Han JI; Lew YJ; Kim JW
Graefes Arch Clin Exp Ophthalmol; 2016 Jan; 254(1):23-30. PubMed ID: 25825231
[TBL] [Abstract][Full Text] [Related]
12. Ranibizumab for vascularized pigment epithelial detachment: 1-year anatomic and functional results.
Chevreaud O; Oubraham H; Cohen SY; Jung C; Blanco-Garavito R; Gherdaoui F; Souied EH
Graefes Arch Clin Exp Ophthalmol; 2017 Apr; 255(4):743-751. PubMed ID: 27913869
[TBL] [Abstract][Full Text] [Related]
13. RETINAL PIGMENT EPITHELIAL TEAR AND ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY IN EXUDATIVE AGE-RELATED MACULAR DEGENERATION: Clinical Course and Long-Term Prognosis.
Heimes B; Farecki ML; Bartels S; Barrelmann A; Gutfleisch M; Spital G; Lommatzsch A; Pauleikhoff D
Retina; 2016 May; 36(5):868-74. PubMed ID: 26655607
[TBL] [Abstract][Full Text] [Related]
14. Ranibizumab in retinal angiomatous proliferation (RAP): influence of RAP stage on visual outcome.
Reche-Frutos J; Calvo-Gonzalez C; PĂ©rez-Trigo S; Fernandez-Perez C; Donate-Lopez J; Garcia-Feijoo J
Eur J Ophthalmol; 2011; 21(6):783-8. PubMed ID: 21484755
[TBL] [Abstract][Full Text] [Related]
15. Intravitreal Anti-Vascular Endothelial Growth Factor Drugs for Retinal Angiomatous Proliferation in Real-Life Practice.
Parodi MB; Donati S; Semeraro F; Danzi P; Introini U; Viola F; Bottoni F; Pucci V; Musig A; Pece A; Azzolini C
J Ocul Pharmacol Ther; 2017 Mar; 33(2):123-127. PubMed ID: 28048946
[TBL] [Abstract][Full Text] [Related]
16. Subfoveal Choroidal Thickness in Eyes with Neovascular Age-Related Macular Degeneration Treated with Anti-Vascular Endothelial Growth Factor Agents.
Kanadani TCM; Veloso CE; Nehemy MB
Ophthalmologica; 2018; 240(4):200-207. PubMed ID: 29768266
[TBL] [Abstract][Full Text] [Related]
17. Ranibizumab Treatment for Pigment Epithelial Detachment Secondary to Neovascular Age-Related Macular Degeneration: Post Hoc Analysis of the HARBOR Study.
Sarraf D; London NJ; Khurana RN; Dugel PU; Gune S; Hill L; Tuomi L
Ophthalmology; 2016 Oct; 123(10):2213-24. PubMed ID: 27566855
[TBL] [Abstract][Full Text] [Related]
18. Two-year course of subfoveal pigment epithelial detachment in eyes with age-related macular degeneration and visual acuity better than 20/40.
Baba T; Kitahashi M; Kubota-Taniai M; Oshitari T; Yamamoto S
Ophthalmologica; 2012; 228(2):102-9. PubMed ID: 22508168
[TBL] [Abstract][Full Text] [Related]
19. Clinical experience of switching anti-VEGF therapy from ranibizumab to aflibercept in age-related choroidal neovascularization.
Van Lancker L; Petrarca R; Moutsouris K; Masaoutis P; Kampougeris G
Eur J Ophthalmol; 2017 May; 27(3):342-345. PubMed ID: 27739561
[TBL] [Abstract][Full Text] [Related]
20. Intravitreal bevacizumab versus ranibizumab for the treatment of retinal angiomatous proliferation.
Parodi MB; Iacono P; Menchini F; Sheth S; Polini G; Pittino R; Bandello F
Acta Ophthalmol; 2013 May; 91(3):267-73. PubMed ID: 21951313
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]